News

Press Releases

February 5, 2024

MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors

January 31, 2024

MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

December 20, 2023

MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference

November 1, 2023

MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer

October 31, 2023

MBX Biosciences to Participate in Stifel 2023 Healthcare Conference

October 16, 2023

MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting

October 9, 2023

MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

October 3, 2023

MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting

September 11, 2023

MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults

August 29, 2023

MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference

August 7, 2023

MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

July 10, 2023

MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer

May 8, 2023

MBX Biosciences to Participate in May Investor Conferences

April 10, 2023

MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference

January 24, 2023

MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference

January 4, 2023

MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

November 14, 2022

MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs

October 5, 2022

MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109

July 26, 2022

MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism

April 11, 2022

MBX Biosciences Appoints Richard B. Bartram as Chief Financial Officer

April 5, 2022

MBX Biosciences Appoints Ora Hirsch Pescovitz, M.D., to Board of Directors

January 5, 2021

MBX Biosciences Appoints Mary Jane Geiger, M.D., Ph.D., as Chief Medical Officer

October 27, 2020

MBX Biosciences Appoints James Cornelius to its Board of Directors

July 27, 2020

MBX Biosciences Closes $34.6 Million Series A Financing in Rare Endocrine Diseases